Mirabegron Teva (Mirabegron)

Mirabegron works by selectively activating β3‑adrenergic receptors on the detrusor muscle of the bladder. This activation raises intracellular cAMP levels, causing the muscle to relax during the storage phase of the urinary cycle, which expands bladder capacity and reduces involuntary contractions.

The appropriate dose of Mirabegron is determined by the prescribing healthcare professional based on the individual’s clinical condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

Safety data for Mirabegron during pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made in consultation with a qualified healthcare provider.

To place an order, submit an enquiry on the Mirabegron Teva product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mirabegron belongs to a different therapeutic class (β3‑adrenergic agonist) than antimuscarinic drugs. While both aim to reduce overactive bladder symptoms, Mirabegron does not carry the anticholinergic side‑effects such as dry mouth and constipation that are common with antimuscarinics, offering an alternative for patients who cannot tolerate those agents.

Mirabegron tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use it after the expiry date indicated on the label.

Mirabegron is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water and not crushed or chewed, unless otherwise directed by a healthcare professional.

Serious risks include significant hypertension, urinary retention that may require catheterisation, and rare but severe allergic reactions such as angioedema. Patients should seek immediate medical attention if they experience a sudden rise in blood pressure, inability to empty the bladder, or swelling of the face, lips, tongue or throat.

Mirabegron is contraindicated in patients with uncontrolled hypertension, severe hepatic impairment, or known hypersensitivity to the drug. Caution is also advised for individuals with moderate renal impairment, narrow‑angle glaucoma, or those taking medications that strongly inhibit CYP2D6 or CYP3A4 without appropriate monitoring.